[{"orgOrder":0,"company":"Chardan Healthcare","sponsor":"Sonnet BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"SON-1010","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Chardan Healthcare","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Chardan Healthcare \/ Chardan Healthcare","highestDevelopmentStatusID":"14","companyTruncated":"Chardan Healthcare \/ Chardan Healthcare"}]

Find Clinical Drug Pipeline Developments & Deals by Chardan Healthcare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Sonnet will use the net proceeds for research and development, including SON-1010, a candidate immunotherapeutic recombinant drug, targeting solid tumors.

                          Brand Name : SON-1010

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 06, 2024

                          Lead Product(s) : SON-1010

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Sonnet BioTherapeutics

                          Deal Size : $5.0 million

                          Deal Type : Public Offering

                          blank